報價延遲最少15分鐘:2024/12/23 22:13 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.94 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.88/-8.54
|
|
企業價值
4.16M
|
| 資產負債 |
|
每股賬面淨值
9.44
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:13 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment ofAlzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing. |